Intellia Therapeutics (NASDAQ:NTLA) Stock: Insider John Leonard Sells 9,000 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John Leonard sold 9,000 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $11.99, for a total transaction of $107,910.00. Following the completion of the sale, the chief executive officer owned 1,138,064 shares in the company, valued at $13,645,387.36. This represents a 0.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Intellia Therapeutics Trading Up 3.8%

Shares of NTLA stock opened at $12.31 on Thursday. Intellia Therapeutics, Inc. has a twelve month low of $7.95 and a twelve month high of $18.48. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -3.66 and a beta of 1.83. The stock has a fifty day simple moving average of $12.17 and a two-hundred day simple moving average of $13.06.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The firm had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $12.98 million. During the same period last year, the business posted ($0.98) earnings per share. The company’s revenue for the quarter was down 46.4% compared to the same quarter last year. Research analysts predict that Intellia Therapeutics, Inc. will post -3.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Intellia Therapeutics in a report on Wednesday, September 9th. Citigroup reissued a “market outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, October 15th. Wall Street Zen cut Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Finally, Evercore raised shares of Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 target price on the stock in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have given a Hold rating and five have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $20.57.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in Intellia Therapeutics by 11.2% during the first quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock valued at $17,713,000 after buying an additional 139,325 shares in the last quarter. Royal Bank of Canada raised its stake in Intellia Therapeutics by 1,082.1% during the first quarter. Royal Bank of Canada now owns 465,499 shares of the company’s stock worth $5,968,000 after acquiring an additional 426,121 shares in the last quarter. Headlands Technologies LLC bought a new stake in Intellia Therapeutics during the 2nd quarter worth approximately $1,595,000. BlackRock Inc. bought a new position in shares of Intellia Therapeutics in the second quarter worth about $260,721,000. Finally, Assenagon Asset Management S.A. bought a new stake in Intellia Therapeutics during the 3rd quarter worth about $3,875,000. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.

Intellia’s pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.